Market News & Trends
Road Ahead Still Difficult for Biosimilar Producers in the US Despite New FDA Guidance on Interchangeability
Following news that the FDA has finalized its guidance on interchangeable biosimilars, Rose Joachim, PhD, Senior Immunology Pharma Analyst at GlobalData, a leading data and…
Codexis Announces CodeEvolver Technology Transfer & License Agreement With Global Pharmaceutical Leader
Codexis, Inc. recently announced the signing of a CodeEvolver platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license…
Adaptimmune & Alpine Immune Sciences Announce Collaboration & License Agreement
Adaptimmune Therapeutics plc and Alpine Immune Sciences, Inc. recently announced a collaboration and license agreement to develop next-generation SPEAR T-cell products that incorporate Alpine’s secreted…
Caris Life Sciences Receives FDA Breakthrough Device Designation
Caris Life Sciences recently announced the US FDA has granted Breakthrough Device designation for the company’s MI Transcriptome companion diagnostic (CDx) test. Designed to detect…
Merus Announces First Patient Treated in Phase 1 Clinical Trial for Advanced Solid Tumors
Merus N.V. recently announced the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the…
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (PDCs) and their associated drug formulations…
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program
Sarepta Therapeutics, Inc. recently announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive…
Octapharma Study Demonstrates Cutaquig Efficacy & Safety
Octapharma presented clinical research results at the Clinical Immunology Society Annual Meeting in Atlanta demonstrating the efficacy and safety of cutaquig [Immune Globulin Subcutaneous (Human)…
Merck Announces Results from Phase 2 Trial
Merck recently announced results from a Phase 2 trial (NCT02982972) evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,…
Eloxx Pharmaceuticals Presents Positive New Data at ARVO
Eloxx Pharmaceuticals, Inc. recently presented new findings related to preclinical inherited retinal disease therapeutic development at the ARVO 2019 Annual Meeting in Vancouver, BC, on…